TherapeuticsMD Inc (TXMD)

NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA

TherapeuticsMD Inc is a micro cap company (market value under $300 million) in the Drug Manufacturers - Specialty & Generic industry.

TherapeuticsMD operates as a pharmaceutical royalty company receiving ongoing payments based on sales of licensed medications. The company holds intellectual property rights to product brands including BIJUVA, IMVEXXY, and prenatal vitamins. It generates revenue through licensing agreements with pharmaceutical partners who commercialize these products across different geographic markets.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the TherapeuticsMD Inc stock.

Our verdict on TXMD

Overvalued: intrinsic value $0.68 per share, market price $1.91, margin of safety -180.2% (as of 2026-11-17).

A 0.7x revenue multiple, discounted for its losses, values the shares at $0.68; the price of $1.91 is 180% above that value.

ETFs with the most weight in TXMD

2 more funds hold it; the full list is part of the paid plan.

More on TXMD

Browse

Peers in Drug Manufacturers - Specialty & Generic

All 82 Drug Manufacturers - Specialty & Generic stocks

Cheaper than TXMD in Drug Manufacturers - Specialty & Generic

26 more in this industry show a wider margin of safety.

Is TXMD undervalued or overvalued?

TXMD is overvalued (as of the 2026-11-17 close). A 0.7x revenue multiple, discounted for its losses, values the shares at $0.68; the price of $1.91 is 180% above that value.

What is the intrinsic value of TXMD?

$0.68 per share (as of the 2026-11-17 close), against a market price of $1.91. That is a margin of safety of -180.2%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.